X4 Pharmaceuticals, Inc 8-K

What Happened

• X4 Pharmaceuticals, Inc. (XFOR) filed an 8-K on May 12, 2026 reporting the results of its Annual Meeting of Stockholders. Shareholders approved an increase of 1,500,000 shares under the Second Amended and Restated 2017 Equity Incentive Plan and re-elected three Class III directors. PricewaterhouseCoopers LLP was ratified as the company’s independent registered public accounting firm for 2026. The 8-K also files the amended equity plan as Exhibit 10.1.

Key Details

• Equity plan: Approved increase of 1,500,000 shares to the Second Amended and Restated 2017 Equity Incentive Plan; full plan filed as Exhibit 10.1.
• Director elections (to serve until 2029 Annual Meeting):
  • Gary J. Bridger, Ph.D. — For: 72,863,269; Withheld: 3,510,134; Broker non-votes: 6,474,104
  • Françoise De Craecker — For: 73,419,383; Withheld: 2,954,020; Broker non-votes: 6,474,104
  • Michael S. Wyzga — For: 71,679,834; Withheld: 4,693,569; Broker non-votes: 6,474,104
• Auditor ratification: PricewaterhouseCoopers LLP ratified as independent auditor for fiscal 2026 — For: 82,734,674; Abstain: 43,841; Against: 68,992.
• Say-on-pay (advisory): Compensation for named executive officers approved — For: 70,932,142; Abstain: 20,692; Against: 5,420,569; Broker non-votes: 6,474,104.
• Vote on equity plan: For: 58,679,552; Abstain: 9,711; Against: 17,684,140; Broker non-votes: 6,474,104.

Why It Matters

• Increasing the equity incentive plan by 1.5 million shares provides the company more capacity to grant stock-based compensation to employees, directors and consultants, which can be used to attract and retain talent and align incentives with shareholders.
• Re-election of the three directors and ratification of PwC maintain board continuity and the company’s audit relationship without change for 2026.
• The say-on-pay approval indicates majority (advisory) shareholder support for executive compensation as disclosed in the proxy, while the detailed vote totals (including broker non‑votes and a notable number of votes against the plan) give investors insight into shareholder sentiment on governance and dilution.